Loading...
XSTOXBRANE
Market cap22mUSD
Dec 23, Last price  
0.16SEK
1D
4.49%
1Q
4.22%
Jan 2017
-99.58%
IPO
-99.50%
Name

Xbrane Biopharma AB

Chart & Performance

D1W1MN
XSTO:XBRANE chart
P/E
—
P/S
1.04
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
107.68%
Rev. gr., 5y
16.15%
Revenues
239m
+314.33%
991,081189,523189,627433,4692,490,11720,771,000112,953,000600,0006,821,00011,533,00057,618,000238,729,000
Net income
-388m
L+125.39%
-834,044-2,107,246-2,572,001-11,844,786-33,288,662-44,935,000-13,236,000-167,474,000-226,792,000-191,012,000-172,226,000-388,172,000
CFO
-407m
L+109.72%
0-2,197,432-2,668,371-12,386,674-39,426,184-36,849,00046,707,000-148,589,000-238,407,000-219,610,000-193,918,000-406,678,000
Earnings
Feb 24, 2025

Profile

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
URL
https://xbrane.com/
IPO date
Feb 03, 2016
Employees
93
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
238,729
314.33%
57,618
399.59%
11,533
69.08%
Cost of revenue
549,155
247,762
204,231
Unusual Expense (Income)
NOPBT
(310,426)
(190,144)
(192,698)
NOPBT Margin
Operating Taxes
3,713
7,786
Tax Rate
NOPAT
(310,426)
(193,857)
(200,484)
Net income
(388,172)
125.39%
(172,226)
-9.83%
(191,012)
-15.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
120,018
170,551
380,870
BB yield
-4.74%
-0.92%
-1.75%
Debt
Debt current
75,871
9,162
7,905
Long-term debt
211,690
67,278
80,857
Deferred revenue
Other long-term liabilities
8
543
Net debt
222,159
(121,499)
(210,363)
Cash flow
Cash from operating activities
(406,678)
(193,918)
(219,610)
CAPEX
(6,791)
(60,125)
(77,350)
Cash from investing activities
(16,769)
(60,125)
(77,350)
Cash from financing activities
298,696
148,864
349,365
FCF
(383,816)
(228,895)
(314,217)
Balance
Cash
65,402
193,994
295,180
Long term investments
3,945
3,945
Excess cash
53,466
195,058
298,548
Stockholders' equity
(1,257,195)
(869,339)
(702,534)
Invested Capital
1,660,017
1,330,262
1,177,424
ROIC
ROCE
EV
Common stock shares outstanding
253,210
225,551
208,115
Price
10.00
-87.82%
82.10
-21.66%
104.80
40.11%
Market cap
2,532,096
-86.33%
18,517,704
-15.10%
21,810,415
82.49%
EV
2,754,255
18,396,205
21,600,052
EBITDA
(288,993)
(173,568)
(179,700)
EV/EBITDA
Interest
2,270
2,583
2,636
Interest/NOPBT